08/06/07

Assay Designs and VWR International enter new distribution agreement
Assay Designs, Inc. and VWR International, LLC have entered into a new distribution agreement via which VWR will offer Assay Design's products to northern American customers. The agreement will benefit both companies by tapping into a larger customer base. VWR's collaborations with top customers in the pharmaceutical and biotech industries will help Assay Designs provide excellent customer service, wider product distribution, and it will also help Assay build stronger customer relationships. Assay Designs develops manufacturing and marketing immunoassay (ELISA) kits, antibodies, and proteins that are used for life sciences research. The company sells these products under the "Assay Designs" and "Stressgen" brand names. VMR International is a leading name in the global research laboratory industry.

Tramiprosate designated as a Fast Track Product by U.S. Food and Drug Administration
Neurochem, Inc. announced that its investigational product candidate, tramiprosate, has been designated as a Fast Track Product for the treatment of Alzheimer's disease by the U.S. Food and Drug Administration (FDA). The Fast Track designation program facilitates quicker reviewing of drugs developed to treat serious and life-threatening conditions, especially if those drugs display potential to meet medical needs for such conditions. Neurochem will hold a meeting with the FDA's neurology products division in August 2007. The agenda for the meeting is to discuss the tramiprosate (ALZHEMED^TM) Phase III program and to give an update on the work accomplished so far on the North American Phase III clinical trial. Neurochem, Inc. emphasizes development and commercialization of innovative therapeutics to address medical needs that demand immediate attention.

Two new appointments to Trimeris board
Trimeris, Inc. has appointed Stephen R. Davis and Barry D. Quart, Pharm.D., to the company's board of directors. Davis is currently serving as executive vice president and chief operating officer of Neurogen Corporation, and Quart is associated with Ardea Biosciences, Inc. in his capacity as president and chief executive officer. The appointments will help Trimeris maximize the value of its FUZEON franchise and develop the next-generation fusion inhibitor, TRI-11404, said Larry Hill, Jr., president and chief operating officer of Trimeris. Hill also said that the extensive biotechnology experience of the two directors, as well as their expertise in product development, commercialization, and corporate finance, will help Trimeris achieve its strategic and financial objectives. A biopharmaceutical company, Trimeris, Inc. focuses on development and commercialization of novel therapeutic agents for the treatment of viral diseases.

You're Brilliant, Extremely Logical, Rational and Have High Standards for Yourself

Top jobs are scattered on the websites of tens of thousands of companies, organizations and other job boards. This presents a difficult theoretical challenge that we help you overcome: By researching, structuring and logically ordering this tremendous variety of jobs in one place, we give you the ability to be resourceful and independently analyze your career options an efficient way. Other job sites are inefficient because they only show you jobs that employers are paying to post there. We actually go out and research jobs and do not accept any money from advertisers for job postings so that we can provide you with unbiased research about every job opening. We give you the resources to analyze your career options in a reserved, calm, independent and analytical manner.

Tell us where to send your access instructions: Your Email: